{"messages":[{"status":"ok","cursor":"1560","count":30,"total":8966}], "collection":[{"rel_doi":"10.1101\/2020.08.04.20168203","rel_title":"Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168203","rel_abs":"Importance: A seroprevalence study can estimate the percentage of people with SARS-CoV-2 antibodies in the general population. Most existing reports have used a convenience sample, which may bias their estimates. Objective: To estimate the seroprevalence of antibodies against SARS-CoV-2 based on a random sample of adults living in Connecticut between March 1 and June 1, 2020. Design: Cross-sectional. Setting: We sought a representative sample of Connecticut residents who completed a survey between June 4 and June 23, 2020 and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and July 6, 2020. Participants: 505 respondents, aged [&ge;]18 years, residing in non-congregate settings who completed both the survey and the serology test. Main outcomes and measures: We estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies among the overall population and across pre-specified subgroups. We also assessed the prevalence of symptomatic illness, risk factors for virus exposure, and self-reported adherence to risk mitigation behaviors among this population. Results: Of the 505 respondents (mean age 50 [{+\/-}17] years; 54% women; 76% non-Hispanic White individuals) included, 32% reported having at least 1 symptom suggestive of COVID-19 since March 1, 2020. Overall, 18 respondents had SARS-CoV-2-specific antibodies, resulting in the state-level weighted seroprevalence of 3.1 (90% CI 1.4-4.8). Individuals who were asymptomatic had significantly lower seroprevalence (0.6% [90% CI 0.0-1.5]) compared with the overall state estimate, while those who reported having had [&ge;]1 and [&ge;]2 symptoms had a seroprevalence of 8.0% (90% CI 3.1-12.9) and 13.0% (90% CI 3.5-22.5), respectively. All 9 of the respondents who reported previously having a positive coronavirus test were positive for SARS-CoV-2-specific IgG antibodies. Nearly two-third of respondents reported having avoided public places (74%) and small gatherings of family or friends (75%), and 97% reported wearing a mask outside their home, at least part of the time. Conclusions and relevance: These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-CoV-2. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents, to prevent resurgence of COVID-19 in this region.","rel_num_authors":19,"rel_authors":[{"author_name":"Shiwani Mahajan","author_inst":"Yale School of Medicine"},{"author_name":"Rajesh Srinivasan","author_inst":"The Gallup Organization"},{"author_name":"Carrie A Redlich","author_inst":"Yale School of Medicine"},{"author_name":"Sara K Huston","author_inst":"The Gallup Organization"},{"author_name":"Kelly M Anastasio","author_inst":"Yale School of Medicine"},{"author_name":"Lisa Cashman","author_inst":"Quest Diagnostics"},{"author_name":"Dan Witters","author_inst":"The Gallup Organization"},{"author_name":"Jenny Marlar","author_inst":"The Gallup Organization"},{"author_name":"Shu-Xia Li","author_inst":"Center for Outcomes Research and Evaluation,Yale-New Haven Hospital"},{"author_name":"Zhenqiu Lin","author_inst":"Yale School of Medicine"},{"author_name":"Domonique Hodge","author_inst":"The Gallup Organization"},{"author_name":"Manas Chattopadhyay","author_inst":"The Gallup Organization"},{"author_name":"Mark D Adams","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Charles Lee","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Lokinendi V Rao","author_inst":"University of Massachusetts Medical School"},{"author_name":"Chris Stewart","author_inst":"The Gallup Organization"},{"author_name":"Karthik Kuppusamy","author_inst":"Quest Diagnostics"},{"author_name":"Albert I Ko","author_inst":"Yale School of Public Health"},{"author_name":"Harlan M Krumholz","author_inst":"Yale School of Medicine"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.04.20164061","rel_title":"Is Higher Viral Load in SARS-CoV-2 Associated With Death?","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20164061","rel_abs":"There is no proven prognostic marker or adequate number of studies in patients hospitalized for coronavirus disease 2019 (COVID19). We conducted a retrospective cohort study of patients hospitalized with COVID19 from March 14 to June 17, 2020, at Sao Paulo Hospital. SARSCoV2 viral load was assessed using the cycle threshold (Ct) values obtained from an RTPCR assay applied to the nasopharyngeal swab samples. Disease severity and patient outcomes were compared. Among the 875 patients, 50.1% (439\/875) had mild, 30.4% (266\/875) moderate, and 19.5% (170\/875) severe disease. A Ct value of <25 (472\/875) indicated a high viral load, which was independently associated with mortality (OR: 0,34; 95% CI: 0,217 to 0,533; p < 0.0001). Admission SARSCoV2 viral load is an important surrogate biomarker of infectivity and is independently associated with mortality among patients hospitalized with COVID19.","rel_num_authors":3,"rel_authors":[{"author_name":"Klinger Soares Faico-Filho","author_inst":"Federal University of Sao Paulo"},{"author_name":"Victor Cabelho Passarelli","author_inst":"Federal University of Sao Paulo"},{"author_name":"Nancy Bellei","author_inst":"Federal University of Sao Paulo"},{"author_name":"Sara K Huston","author_inst":"The Gallup Organization"},{"author_name":"Kelly M Anastasio","author_inst":"Yale School of Medicine"},{"author_name":"Lisa Cashman","author_inst":"Quest Diagnostics"},{"author_name":"Dan Witters","author_inst":"The Gallup Organization"},{"author_name":"Jenny Marlar","author_inst":"The Gallup Organization"},{"author_name":"Shu-Xia Li","author_inst":"Center for Outcomes Research and Evaluation,Yale-New Haven Hospital"},{"author_name":"Zhenqiu Lin","author_inst":"Yale School of Medicine"},{"author_name":"Domonique Hodge","author_inst":"The Gallup Organization"},{"author_name":"Manas Chattopadhyay","author_inst":"The Gallup Organization"},{"author_name":"Mark D Adams","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Charles Lee","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Lokinendi V Rao","author_inst":"University of Massachusetts Medical School"},{"author_name":"Chris Stewart","author_inst":"The Gallup Organization"},{"author_name":"Karthik Kuppusamy","author_inst":"Quest Diagnostics"},{"author_name":"Albert I Ko","author_inst":"Yale School of Public Health"},{"author_name":"Harlan M Krumholz","author_inst":"Yale School of Medicine"}],"version":"2","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168682","rel_title":"The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine\/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing Antibody","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168682","rel_abs":"Background: COVID-19 patients show a wide clinical spectrum ranging from mild respiratory symptoms to severe and fatal disease, and older individuals are known to be affected more severely. Neutralizing antibody for viruses is critical for their elimination, and increased cytokine\/chemokine levels are thought to be related to COVID-19 severity. However, the trend of the neutralizing antibody production and cytokine\/chemokine levels during the clinical course of COVID-19 patients with differing levels of severity has not been established. Methods: We serially collected 45 blood samples from 12 patients with different levels of COVID-19 severity, and investigated the trend of neutralizing antibody production using authentic SARS-CoV-2 and cytokine\/chemokine release in the patients' clinical courses. Results: All 12 individuals infected with SARS-CoV-2 had the neutralizing antibody against it, and the antibodies were induced at approx. 4-10 days after the patients' onsets. The antibodies in the critical and severe cases showed high neutralizing activity in all clinical courses. Most cytokine\/chemokine levels were clearly high in the critical patients compared to those with milder symptoms. Conclusion: Neutralizing antibodies against SARS-CoV-2 were induced at a high level in the severe COVID-19 patients, indicating that abundant virus replication occurred. Cytokines\/chemokines were expressed more in the critical patients, indicating that high productions of cytokines\/chemokines have roles in the disease severity. These results may indicate that plasma or neutralizing antibody therapy could be a first-line treatment for older patients to eliminate the virus, and corticosteroid therapy could be effective to suppress the cytokine storm after the viral genome's disappearance.","rel_num_authors":9,"rel_authors":[{"author_name":"Lidya Handayani Tjan","author_inst":"Kobe University"},{"author_name":"Tatsuya Nagano","author_inst":"Kobe University"},{"author_name":"Koichi Furukawa","author_inst":"Kobe University"},{"author_name":"Mitsuhiro Nishimura","author_inst":"Kobe University"},{"author_name":"Jun Arii","author_inst":"Kobe University"},{"author_name":"Sayo Fujinaka","author_inst":"Hyogo Prefectural Kakogawa Medical Center"},{"author_name":"Sachiyo Iwata","author_inst":"Hyogo Prefectural Kakogawa Medical Center"},{"author_name":"Yoshihiro Nishimura","author_inst":"Kobe University"},{"author_name":"Yasuko Mori","author_inst":"Kobe University"},{"author_name":"Zhenqiu Lin","author_inst":"Yale School of Medicine"},{"author_name":"Domonique Hodge","author_inst":"The Gallup Organization"},{"author_name":"Manas Chattopadhyay","author_inst":"The Gallup Organization"},{"author_name":"Mark D Adams","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Charles Lee","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Lokinendi V Rao","author_inst":"University of Massachusetts Medical School"},{"author_name":"Chris Stewart","author_inst":"The Gallup Organization"},{"author_name":"Karthik Kuppusamy","author_inst":"Quest Diagnostics"},{"author_name":"Albert I Ko","author_inst":"Yale School of Public Health"},{"author_name":"Harlan M Krumholz","author_inst":"Yale School of Medicine"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168617","rel_title":"Rapid, reliable, and cheap point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP (Cap-iLAMP)","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168617","rel_abs":"Efforts to contain the spread of SARS-CoV-2 have spurred the need for reliable, rapid, and cost-effective diagnostic methods which can easily be applied to large numbers of people. However, current standard protocols for the detection of viral nucleic acids while sensitive, require a high level of automation, sophisticated laboratory equipment and trained personnel to achieve throughputs that allow whole communities to be tested on a regular basis. Here we present Cap-iLAMP (capture and improved loop-mediated isothermal amplification). This method combines a hybridization capture-based RNA extraction of non-invasive gargle lavage samples to concentrate samples and remove inhibitors with an improved colorimetric RT-LAMP assay and smartphone-based color scoring. Cap-iLAMP is compatible with point-of-care testing and enables the detection of SARS-CoV-2 positive samples in less than one hour. In contrast to direct addition of the sample to improved LAMP (iLAMP), Cap-iLAMP does not result in false positives and single infected samples can be detected in a pool among 25 uninfected samples, thus reducing the technical cost per test to ~1 Euro per individual.","rel_num_authors":7,"rel_authors":[{"author_name":"Lukas Bokelmann","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Olaf Nickel","author_inst":"Department of Laboratory Medicine, Hospital St. Georg"},{"author_name":"Tomislav Maricic","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Svante Paabo","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Matthias Meyer","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Stephan Borte","author_inst":"Department of Laboratory Medicine, Hospital St. Georg"},{"author_name":"Stephan Riesenberg","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Yoshihiro Nishimura","author_inst":"Kobe University"},{"author_name":"Yasuko Mori","author_inst":"Kobe University"},{"author_name":"Zhenqiu Lin","author_inst":"Yale School of Medicine"},{"author_name":"Domonique Hodge","author_inst":"The Gallup Organization"},{"author_name":"Manas Chattopadhyay","author_inst":"The Gallup Organization"},{"author_name":"Mark D Adams","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Charles Lee","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Lokinendi V Rao","author_inst":"University of Massachusetts Medical School"},{"author_name":"Chris Stewart","author_inst":"The Gallup Organization"},{"author_name":"Karthik Kuppusamy","author_inst":"Quest Diagnostics"},{"author_name":"Albert I Ko","author_inst":"Yale School of Public Health"},{"author_name":"Harlan M Krumholz","author_inst":"Yale School of Medicine"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.200691","rel_title":"Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and their Augmentation by Compact Joint Sets","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.04.200691","rel_abs":"Subunit vaccines induce immunity to a pathogen by presenting a component of the pathogen and thus inherently limit the representation of pathogen peptides for cellular immunity based memory. We find that SARS-CoV-2 subunit peptides may not be robustly displayed by the Major Histocompatibility Complex (MHC) molecules in certain individuals. We introduce an augmentation strategy for subunit vaccines that adds a small number of peptides to a vaccine to improve the population coverage of pathogen peptide display. We augment a subunit vaccine by selecting additional pathogen peptides to maximize the total number of vaccine peptide hits against the distribution of MHC haplotypes in a population. For each subunit we design independent MHC class I and MHC class II peptide sets for augmentation, and alternatively design a combined set of peptides for MHC class I and class II display. We evaluate the population coverage of 9 different subunits of SARS-CoV-2, including 5 functional domains and 4 full proteins, and augment each of them to fill a predicted coverage gap. We predict that a SARS-CoV-2 receptor binding domain subunit vaccine will have fewer than six peptide-HLA hits with [&le;] 50 nM binding affinity per individual in 51.31% (class I) and 32.99% (class II) of the population, and with augmentation, the uncovered population is predicted to be reduced to 0.54% (class I) and 1.46% (class II). We find that a joint set of pathogen peptides for MHC class I and class II display is predicted to produce a more compact vaccine design than using independent sets for MHC class I and class II. We provide an open source implementation of our design methods (OptiVax), vaccine evaluation tool (EvalVax), as well as the data used in our design efforts here: https:\/\/github.com\/gifford-lab\/optivax\/tree\/master\/augmentation.","rel_num_authors":3,"rel_authors":[{"author_name":"Ge Liu","author_inst":"MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA; MIT Electrical Engineering and Computer Science, Cambridge, MA, USA"},{"author_name":"Brandon Carter","author_inst":"MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA; MIT Electrical Engineering and Computer Science, Cambridge, MA, USA"},{"author_name":"David K. Gifford","author_inst":"MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA; MIT Electrical Engineering and Computer Science, Cambridge, MA, USA; MIT Biolog"},{"author_name":"Svante Paabo","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Matthias Meyer","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Stephan Borte","author_inst":"Department of Laboratory Medicine, Hospital St. Georg"},{"author_name":"Stephan Riesenberg","author_inst":"Max Planck Institute for Evolutionary Anthropology"},{"author_name":"Yoshihiro Nishimura","author_inst":"Kobe University"},{"author_name":"Yasuko Mori","author_inst":"Kobe University"},{"author_name":"Zhenqiu Lin","author_inst":"Yale School of Medicine"},{"author_name":"Domonique Hodge","author_inst":"The Gallup Organization"},{"author_name":"Manas Chattopadhyay","author_inst":"The Gallup Organization"},{"author_name":"Mark D Adams","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Charles Lee","author_inst":"The Jackson Laboratory for Genomic Medicine"},{"author_name":"Lokinendi V Rao","author_inst":"University of Massachusetts Medical School"},{"author_name":"Chris Stewart","author_inst":"The Gallup Organization"},{"author_name":"Karthik Kuppusamy","author_inst":"Quest Diagnostics"},{"author_name":"Albert I Ko","author_inst":"Yale School of Public Health"},{"author_name":"Harlan M Krumholz","author_inst":"Yale School of Medicine"}],"version":"1","license":"cc_no","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.08.05.20168930","rel_title":"Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168930","rel_abs":"New Zealand, a geographically remote Pacific island with easily sealable borders, implemented a nation-wide lockdown of all non-essential services to curb the spread of COVID-19. New Zealand has now effectively eliminated the virus, with low numbers of new cases limited to new arrivals in managed quarantine facilities at the border. Here, we generated 649 SARS-CoV-2 genome sequences from infected patients in New Zealand with samples collected between 26 February and 22 May 2020, representing 56% of all confirmed cases in this time period. Despite its remoteness, the viruses imported into New Zealand represented nearly all of the genomic diversity sequenced from the global virus population. The proportion of D614G variants in the virus spike protein increased over time due to an increase in their importation frequency, rather than selection within New Zealand. These data also helped to quantify the effectiveness of public health interventions. For example, the effective reproductive number, Re, of New Zealand's largest cluster decreased from 7 to 0.2 within the first week of lockdown. Similarly, only 19% of virus introductions into New Zealand resulted in a transmission lineage of more than one additional case. Most of the cases that resulted in a transmission lineage originated from North America, rather than from Asia where the virus first emerged or from the nearest geographical neighbour, Australia. Genomic data also helped link more infections to a major transmission cluster than through epidemiological data alone, providing probable sources of infections for cases in which the source was unclear. Overall, these results demonstrate the utility of genomic pathogen surveillance to inform public health and disease mitigation.","rel_num_authors":21,"rel_authors":[{"author_name":"Jemma L Geoghegan","author_inst":"University of Otago"},{"author_name":"Xiaoyun Ren","author_inst":"Institute of Environmental Science and Research"},{"author_name":"Matthew Storey","author_inst":"Institute of Environmental Science and Research"},{"author_name":"James Hadfield","author_inst":"Fred Hutchinson Cancer Research Centre"},{"author_name":"Lauren Jelley","author_inst":"Institute of Environmental Science and Research"},{"author_name":"Sarah Jefferies","author_inst":"Institute of Environmental Science and Research"},{"author_name":"Jill Sherwood","author_inst":"Institute of Environmental Science and Research"},{"author_name":"Shevaun Paine","author_inst":"Institute of Environmental Science and Research"},{"author_name":"Sue Huang","author_inst":"Institute of Environmental Science and Research"},{"author_name":"Jordan Douglas","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Fabio K Mendes","author_inst":"University of Auckland"},{"author_name":"Andrew Sporle","author_inst":"McDonaldSporle Ltd., Auckland"},{"author_name":"Michael G Baker","author_inst":"Department of Public Health, University of Otago"},{"author_name":"David R Murdoch","author_inst":"Department of Pathology and Biomedical Science, University of Otago"},{"author_name":"Nigel French","author_inst":"Massey University"},{"author_name":"Colin R Simpson","author_inst":"School of Health, Faculty of Health, Victoria University of Wellington"},{"author_name":"David Welch","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168815","rel_title":"Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM\/IgG antibody test","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168815","rel_abs":"The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Lifting confinement restriction and resuming to normality depends greatly on COVID-19 immunity screening. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM\/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n=45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. We also studied antibody response in relation to time after symptom onset and disease severity, and observed an increase in antibody reactivity and distinct distribution patterns of IgM and IgG following disease progression. The total IgM and IgG detection is 63% in patients with < 2 weeks from disease onset; 85% in non-hospitalized patients with > 2 weeks disease duration; and 91% in hospitalized patients with > 2 weeks disease duration. We also compared different blood sample types and suggest a potentially higher sensitivity by serum\/plasma comparing with whole blood measurement. To study the specificity of the test, we used 69 sera\/plasma samples collected between 2016-2018 prior to the COVID-19 pandemic, and obtained a test specificity of 97%. In summary, our study provides a comprehensive validation of the rapid COVID-19 IgM\/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our study supports that the rapid COVID-19 IgM\/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.","rel_num_authors":12,"rel_authors":[{"author_name":"Yang De Marinis","author_inst":"Lund University"},{"author_name":"Torgny Sunnerhagen","author_inst":"Lund University"},{"author_name":"Pradeep Bompada","author_inst":"Lund University"},{"author_name":"Anna Blackberg","author_inst":"Lund University"},{"author_name":"Runtao Yang","author_inst":"Shandong University"},{"author_name":"Joel Svensson","author_inst":"Lund University"},{"author_name":"Ola Ekstrom","author_inst":"Lund University"},{"author_name":"Karl-Fredrik Eriksson","author_inst":"Lund University"},{"author_name":"Ola Hansson","author_inst":"Lund University"},{"author_name":"Leif Groop","author_inst":"Lund University"},{"author_name":"Isabel Goncalves","author_inst":"Lund University"},{"author_name":"Magnus Rasmussen","author_inst":"Lund University"},{"author_name":"Michael G Baker","author_inst":"Department of Public Health, University of Otago"},{"author_name":"David R Murdoch","author_inst":"Department of Pathology and Biomedical Science, University of Otago"},{"author_name":"Nigel French","author_inst":"Massey University"},{"author_name":"Colin R Simpson","author_inst":"School of Health, Faculty of Health, Victoria University of Wellington"},{"author_name":"David Welch","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168971","rel_title":"Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168971","rel_abs":"Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role in the development of vaccines and antibody-based interventions. We report systemic and mucosal antibody responses in convalescent individuals who experienced varying disease severity. Robust antibody responses to diverse SARS-CoV-2 antigens and evidence of elevated responses to endemic CoV were observed among convalescent donors. SARS-CoV-2-specific IgA and IgG responses were often negatively correlated, particularly in mucosal samples, suggesting subject-intrinsic biases in isotype switching. Assessment of antibody-mediated effector functions revealed an inverse correlation between systemic and mucosal neutralization activity and site-dependent differences in the isotype of neutralizing antibodies. Serum neutralization correlated with systemic anti-SARS-CoV-2 IgG and IgM response magnitude, while mucosal neutralization was associated with nasal SARS-CoV-2-specific IgA. These findings begin to map how diverse Ab characteristics relate to Ab functions and outcomes of infection, informing public health assessment strategies and vaccine development efforts.","rel_num_authors":10,"rel_authors":[{"author_name":"Savannah E Butler","author_inst":"Dartmouth College"},{"author_name":"Andrew R Crowley","author_inst":"Dartmouth College"},{"author_name":"Harini Natarajan","author_inst":"Dartmouth College"},{"author_name":"Shiwei Xu","author_inst":"Dartmouth College"},{"author_name":"Joshua A Weiner","author_inst":"Dartmouth College"},{"author_name":"Jiwon Lee","author_inst":"Dartmouth College"},{"author_name":"Wendy F Wieland-Alter","author_inst":"Dartmouth-Hitchcock Medical Center"},{"author_name":"Ruth I Connor","author_inst":"Dartmouth-Hitchcock Medical Center"},{"author_name":"Peter F Wright","author_inst":"Dartmouth-Hitchcock Medical Center"},{"author_name":"Margaret E Ackerman","author_inst":"Dartmouth College"},{"author_name":"Isabel Goncalves","author_inst":"Lund University"},{"author_name":"Magnus Rasmussen","author_inst":"Lund University"},{"author_name":"Michael G Baker","author_inst":"Department of Public Health, University of Otago"},{"author_name":"David R Murdoch","author_inst":"Department of Pathology and Biomedical Science, University of Otago"},{"author_name":"Nigel French","author_inst":"Massey University"},{"author_name":"Colin R Simpson","author_inst":"School of Health, Faculty of Health, Victoria University of Wellington"},{"author_name":"David Welch","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168948","rel_title":"Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168948","rel_abs":"The COVID-19 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has overwhelmed health systems worldwide and highlighted limitations of diagnostic testing. Several types of diagnostics including RT-PCR-based assays, antigen detection by lateral flow assays and antibody-based assays have been developed and deployed in a short time. However, many of these assays are lacking in sensitivity and\/or specificity. Here, we describe an immunoaffinity purification followed by high resolution mass spectrometry-based targeted assay capable of detecting viral antigen in nasopharyngeal swab samples of SARS-CoV-2 infected individuals. Based on our discovery experiments using purified virus, recombinant viral protein and nasopharyngeal swab samples from COVID-19 positive patients, nucleocapsid protein was selected as a target antigen. We then developed an automated antibody capture-based workflow coupled to targeted high-field asymmetric ion mobility spectrometry (FAIMS) - parallel reaction monitoring (PRM) assays on an Orbitrap Exploris 480 mass spectrometer. An ensemble machine learning-based model for determining COVID-19 positive samples was created using fragment ion intensities in the PRM data. This resulted in 97.8% sensitivity and 100% specificity with RT-PCR-based molecular testing as the gold standard. Our results demonstrate that direct detection of infectious agents from clinical samples by mass spectrometry-based assays have potential to be deployed as diagnostic assays in clinical laboratories.","rel_num_authors":17,"rel_authors":[{"author_name":"Santosh Renuse","author_inst":"Mayo Clinic"},{"author_name":"Patrick M Vanderboom","author_inst":"Mayo Clinic"},{"author_name":"Anthony D. Maus","author_inst":"Mayo Clinic"},{"author_name":"Jennifer V. Kemp","author_inst":"Mayo Clinic"},{"author_name":"Kari M. Gurtner","author_inst":"Mayo Clinic"},{"author_name":"Anil K. Madugundu","author_inst":"Mayo Clinic"},{"author_name":"Sandip Chavan","author_inst":"Mayo Clinic"},{"author_name":"Jane A. Peterson","author_inst":"Mayo Clinic"},{"author_name":"Benjamin J. Madden","author_inst":"Mayo Clinic"},{"author_name":"Kiran K. Mangalaparthi","author_inst":"Mayo Clinic"},{"author_name":"Dong-Gi Mun","author_inst":"Mayo Clinic"},{"author_name":"Smrita Singh","author_inst":"Mayo Clinic"},{"author_name":"Benjamin R. Kipp","author_inst":"Mayo Clinic"},{"author_name":"Surendra Dasari","author_inst":"Mayo Clinic"},{"author_name":"Ravinder J. Singh","author_inst":"Mayo Clinic"},{"author_name":"Stefan K. Grebe","author_inst":"Mayo Clinic"},{"author_name":"Akhilesh Pandey","author_inst":"Mayo Clinic"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168146","rel_title":"Clinical Mortality Review in a Large COVID-19 Cohort","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168146","rel_abs":"Background: Northwell Health (Northwell), an integrated health system in New York, treated more than 15000 inpatients with coronavirus disease (COVID-19) at the US epicenter of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We describe the demographic characteristics of COVID-19 mortalities, observation of frequent rapid response teams (RRT)\/cardiac arrest (CA) calls for non-intensive care unit (ICU) patients, and factors that contributed to RRT\/CA calls. Methods: A team of registered nurses reviewed medical records of inpatients who tested positive for SARS-CoV-2 via polymerase chain reaction (PCR) before or on admission and died between March 13 (first Northwell inpatient expiration) and April 30, 2020 at 15 Northwell hospitals. Findings for these patients were abstracted into a database and statistically analyzed. Findings: Of 2634 COVID-19 mortalities, 56.1% had oxygen saturation levels greater than or equal to 90% on presentation and required no respiratory support. At least one RRT\/CA was called on 42.2% of patients at a non-ICU level of care. Before the RRT\/CA call, the most recent oxygen saturation levels for 76.6% of non-ICU patients were at least 90%. At the time RRT\/CA was called, 43.1% had an oxygen saturation less than 80%. Interpretation: This study represents one of the largest cohorts of reviewed mortalities that also captures data in non-structured fields. Approximately 50% of deaths occurred at a non-ICU level of care, despite admission to the appropriate care setting with normal staffing. The data imply a sudden, unexpected deterioration in respiratory status requiring RRT\/CA in a large number of non-ICU patients. Patients admitted to a non-ICU level of care suffer rapid clinical deterioration, often with a sudden decrease in oxygen saturation. These patients could benefit from additional monitoring (eg, continuous central oxygenation saturation), although this approach warrants further study.","rel_num_authors":7,"rel_authors":[{"author_name":"Mark P Jarrett","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Susanne F Schultz","author_inst":"Northwell Health"},{"author_name":"Julie S Lyall","author_inst":"Northwell Health"},{"author_name":"Jason J Wang","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Lori Stier","author_inst":"Northwell Health"},{"author_name":"Marcella De Geronimo","author_inst":"NorthwellHealth"},{"author_name":"Karen L Nelson","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Jane A. Peterson","author_inst":"Mayo Clinic"},{"author_name":"Benjamin J. Madden","author_inst":"Mayo Clinic"},{"author_name":"Kiran K. Mangalaparthi","author_inst":"Mayo Clinic"},{"author_name":"Dong-Gi Mun","author_inst":"Mayo Clinic"},{"author_name":"Smrita Singh","author_inst":"Mayo Clinic"},{"author_name":"Benjamin R. Kipp","author_inst":"Mayo Clinic"},{"author_name":"Surendra Dasari","author_inst":"Mayo Clinic"},{"author_name":"Ravinder J. Singh","author_inst":"Mayo Clinic"},{"author_name":"Stefan K. Grebe","author_inst":"Mayo Clinic"},{"author_name":"Akhilesh Pandey","author_inst":"Mayo Clinic"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168716","rel_title":"Rapid systematic review of the sensitivity of SARS-CoV-2 molecular testing on saliva compared to nasopharyngeal swabs","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168716","rel_abs":"ABSTRACT Background: Nasopharyngeal sampling has been the standard collection method for COVID-19 testing. Due to its invasive nature and risk of contamination for health care workers who collect the sample, non-invasive and safe sampling methods like saliva, can be used alternatively. Methods: A rapid systematic search was performed in PubMed and medRxiv, with the last retrieval on June 6th, 2020. Studies were included if they compared saliva with nasopharyngeal sampling for the detection of SARS-CoV-2 RNA using the same RT-qPCR applied on both types of samples. The primary outcome of interest was the relative sensitivity of SARS-CoV-2 testing on saliva versus nasopharyngeal samples (used as the comparator test). A secondary outcome was the proportion of nasopharyngeal-positive patients that tested also positive on a saliva sample. Results: Eight studies were included comprising 1070 saliva-nasopharyngeal sample pairs allowing assessment of the first outcome. The relative sensitivity of SARS-CoV-2 testing on saliva versus nasopharyngeal samples was 0.97 (95% CI=0.92-1.02). The second outcome incorporated patient data (n=257) from four other studies (n=97 patients) pooled with four studies from the first outcome (n=160 patients). This resulted in a pooled proportion of nasopharyngeal positive cases that was also positive on saliva of 86% (95% CI=77-93%). Discussion: Saliva could potentially be considered as an alternative sampling method when compared to nasopharyngeal swabs. However, studies included in this review often were small and involved inclusion of subjects with insufficient information on clinical covariates. Most studies included patients who were symptomatic (78%, 911\/1167). Therefore, additional and larger studies should be performed to verify the relative performance of saliva in the context of screening of asymptomatic populations and contact-tracing.","rel_num_authors":6,"rel_authors":[{"author_name":"Eliana Peeters","author_inst":"Sciensano"},{"author_name":"Sharon Kaur Dhillon Ajit Singh","author_inst":"Sciensano"},{"author_name":"Jo Vandesompele","author_inst":"Biogazelle"},{"author_name":"Pieter Mestdagh","author_inst":"Biogazelle"},{"author_name":"Veronik Hutse","author_inst":"Sciensano"},{"author_name":"Marc Arbyn","author_inst":"Sciensano"},{"author_name":"Karen L Nelson","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Jane A. Peterson","author_inst":"Mayo Clinic"},{"author_name":"Benjamin J. Madden","author_inst":"Mayo Clinic"},{"author_name":"Kiran K. Mangalaparthi","author_inst":"Mayo Clinic"},{"author_name":"Dong-Gi Mun","author_inst":"Mayo Clinic"},{"author_name":"Smrita Singh","author_inst":"Mayo Clinic"},{"author_name":"Benjamin R. Kipp","author_inst":"Mayo Clinic"},{"author_name":"Surendra Dasari","author_inst":"Mayo Clinic"},{"author_name":"Ravinder J. Singh","author_inst":"Mayo Clinic"},{"author_name":"Stefan K. Grebe","author_inst":"Mayo Clinic"},{"author_name":"Akhilesh Pandey","author_inst":"Mayo Clinic"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168757","rel_title":"Epidemiology of Reopening in the COVID-19 Pandemic in the United States, Europe and Asia","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168757","rel_abs":"Since the discovery of the novel coronavirus (SARS-CoV-2), COVID-19 has become a global healthcare and economic crisis. The United States (US) and Europe exhibited wide impacts from the virus with more than six million cases by the time of our analysis. To inhibit spread, stay-at-home orders and other non-pharmaceutical interventions (NPIs) were instituted. Beginning late April 2020, some US states, European, and Asian countries lifted restrictions and started the reopening phases. In this study, the changes of confirmed cases, hospitalizations, and deaths were analyzed after reopening for 11 countries and 40 US states using an interrupted time series analysis. Additionally, the distribution of these categories was further analyzed by age due to the known increased risk in elderly patients. Reopening had varied effects on COVID-19 cases depending on the region. Recent increases in cases did not fully translate into increased deaths. Eight countries had increased cases after reopening while only two countries showed the same trend in deaths. In the US, 30 states had observed increases in cases while only seven observed increased deaths. In addition, we found that states with later reopening dates were more likely to have significant decreases in cases, hospitalizations, and deaths. Furthermore, age distributions through time were analyzed in relation to COVID-19 in the US. Younger age groups typically had an increased share of cases after reopening.","rel_num_authors":5,"rel_authors":[{"author_name":"Weiqi Zhang","author_inst":"Merck Holding (China), Shanghai, China, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Alina Oltean","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Scott Nichols","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Fuad Odeh","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Fei Zhong","author_inst":"MilliporeSigma, St. Louis, Missouri, a business of Merck KGaA, Darmstadt, Germany"},{"author_name":"Marc Arbyn","author_inst":"Sciensano"},{"author_name":"Karen L Nelson","author_inst":"Donald and Barbara Zucker School at Hofstra\/Northwell"},{"author_name":"Jane A. Peterson","author_inst":"Mayo Clinic"},{"author_name":"Benjamin J. Madden","author_inst":"Mayo Clinic"},{"author_name":"Kiran K. Mangalaparthi","author_inst":"Mayo Clinic"},{"author_name":"Dong-Gi Mun","author_inst":"Mayo Clinic"},{"author_name":"Smrita Singh","author_inst":"Mayo Clinic"},{"author_name":"Benjamin R. Kipp","author_inst":"Mayo Clinic"},{"author_name":"Surendra Dasari","author_inst":"Mayo Clinic"},{"author_name":"Ravinder J. Singh","author_inst":"Mayo Clinic"},{"author_name":"Stefan K. Grebe","author_inst":"Mayo Clinic"},{"author_name":"Akhilesh Pandey","author_inst":"Mayo Clinic"},{"author_name":"Alexei J Drummond","author_inst":"Centre for Computational Evolution, School of Computer Science, University of Auckland"},{"author_name":"Edward C Holmes","author_inst":"University of Sydney"},{"author_name":"Sebastian Duchene","author_inst":"University of Melbourne"},{"author_name":"Joep de Ligt","author_inst":"Institute of Environmental Science and Research"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20167874","rel_title":"Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20167874","rel_abs":"The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is due to the high rates of transmission by individuals who are asymptomatic at the time of transmission. Frequent, widespread testing of the asymptomatic population for SARS-CoV-2 is essential to suppress viral transmission and is a key element in safely reopening society. Despite increases in testing capacity, multiple challenges remain in deploying traditional reverse transcription and quantitative PCR (RT-qPCR) tests at the scale required for population screening of asymptomatic individuals. We have developed SwabSeq, a high-throughput testing platform for SARS-CoV-2 that uses next-generation sequencing as a readout. SwabSeq employs sample-specific molecular barcodes to enable thousands of samples to be combined and simultaneously analyzed for the presence or absence of SARS-CoV-2 in a single run. Importantly, SwabSeq incorporates an in vitro RNA standard that mimics the viral amplicon, but can be distinguished by sequencing. This standard allows for end-point rather than quantitative PCR, improves quantitation, reduces requirements for automation and sample-to-sample normalization, enables purification-free detection, and gives better ability to call true negatives. We show that SwabSeq can test nasal and oral specimens for SARS-CoV-2 with or without RNA extraction while maintaining analytical sensitivity better than or comparable to that of fluorescence-based RT-qPCR tests. SwabSeq is simple, sensitive, flexible, rapidly scalable, inexpensive enough to test widely and frequently, and can provide a turn around time of 12 to 24 hours.","rel_num_authors":31,"rel_authors":[{"author_name":"Joshua S. Bloom","author_inst":"University of California, Los Angeles"},{"author_name":"Eric M. Jones","author_inst":"Octant Inc."},{"author_name":"Molly Gasperini","author_inst":"Octant Inc."},{"author_name":"Nathan B. Lubock","author_inst":"Octant Inc."},{"author_name":"Laila Sathe","author_inst":"University of California, Los Angeles"},{"author_name":"Chetan Munugala","author_inst":"University of California, Los Angeles"},{"author_name":"A. Sina Booeshaghi","author_inst":"California Institute of Technology"},{"author_name":"Oliver F. Brandenberg","author_inst":"University of California, Los Angeles"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168450","rel_title":"Social Behaviors Associated with a Positive COVID-19 Test Result","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168450","rel_abs":"Objective: To compare behaviors of individuals who tested positive for COVID-19 relative to non-infected individuals. Methods: We sent COVID positive cases and age\/gender matched controls a survey regarding their social behaviors via MyChart (online patient portal). We called cases if they did not complete the electronic survey within two days. Data was collected from May-June 2020. Survey responses for cases without a close contact and controls were compared using Pearson chi-square or Fishers Exact tests as appropriate. Results: A total of 339 participants completed the survey (113 cases, 226 controls); 45 (40%) cases had known contact with COVID-19. Cases were more likely to have recently traveled (4% vs. 0%, p=0.01) or to work outside the home (40% vs. 25%, p=0.02). There was no difference in the rates of attending private or public gatherings, mask\/glove use, hand-washing, cleaning surfaces and cleaning mail\/groceries between cases and controls. Conclusions: Sixty percent of cases had no known contact with COVID-19, indicating ongoing community transmission and underlining the importance of contact tracing. The greater percentage of cases who work outside the home provides further evidence for social distancing.","rel_num_authors":8,"rel_authors":[{"author_name":"Sidra Speaker","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Christine Marie Doherty","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Elizabeth R Pfoh","author_inst":"Cleveland Clinic"},{"author_name":"Aaron Dunn","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Bryan Hair","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Victoria Shaker","author_inst":"Cleveland Clinic"},{"author_name":"Lynn Daboul","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Michael B Rothberg","author_inst":"Cleveland Clinic"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168468","rel_title":"Extended lifetime of respiratory droplets in a turbulent vapour puff and its implications on airborne disease transmission","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168468","rel_abs":"To mitigate the COVID-19 pandemic, it is key to slow down the spreading of the life-threatening coronavirus (SARS-CoV-2). This spreading mainly occurs through virus-laden droplets expelled at speaking, screaming, shouting, singing, coughing, sneezing, or even breathing [1-7]. To reduce infections through such respiratory droplets, authorities all over the world have introduced the so-called \"2-meter distance rule\" or \"6-foot rule\". However, there is increasing empirical evidence, e.g. through the analysis of super-spreading events [6, 8-11], that airborne transmission of the coronavirus over much larger distances plays a major role [1-3, 7, 12-15], with tremendous implications for the risk assessment of coronavirus transmission. It is key to better and fundamentally understand the environmental ambient conditions under which airborne transmission of the coronavirus is likely to occur, in order to be able to control and adapt them. Here we employ direct numerical simulations of a typical respiratory aerosol in a turbulent jet of the respiratory event within a Lagrangian-Eulerian approach [16-18] with 5000 droplets, coupled to the ambient velocity, temperature, and humidity fields to allow for exchange of mass and heat [19] and to realistically account for the droplet evaporation under different ambient conditions. We found that for an ambient relative humidity of 50% the lifetime of the smallest droplets of our study with initial diameter of 10 m gets extended by a factor of more than 30 as compared to what is suggested by the classical picture of Wells [20, 21], due to collective effects during droplet evaporation and the role of the respiratory humidity [22], while the larger droplets basically behave ballistically. With increasing ambient relative humidity the extension of the lifetimes of the small droplets further increases and goes up to 150 times for 90% relative humidity, implying more than two meters advection range of the respiratory droplets within one second. Smaller droplets live even longer and travel further. Our results may explain why COVID-19 superspreading events can occur for large ambient relative humidity such as in cooled-down meat-processing plants [10] or in pubs with poor ventilation. We anticipate our tool and approach to be starting points for larger parameter studies and for optimizing ventilation and indoor humidity controlling concepts, which in the upcoming autumn and winter both will be key in mitigating the COVID-19 pandemic.","rel_num_authors":6,"rel_authors":[{"author_name":"Kai Leong Chong","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Chong Shen Ng","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Naoki Hori","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Rui Yang","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Roberto Verzicco","author_inst":"University of Rome 'Tor Vergata', Roma, Italy"},{"author_name":"Detlef Lohse","author_inst":"University of Twente, Enschede, Netherlands"},{"author_name":"Lynn Daboul","author_inst":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University"},{"author_name":"Michael B Rothberg","author_inst":"Cleveland Clinic"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.04.20168351","rel_title":"Estimation of Effective Reproduction Number for COVID-19 in Bangladesh and its districts","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.04.20168351","rel_abs":"Background Bangladesh is going through an unprecedented crisis since the onset of the COVID-19 pandemic. Throughout the COVID-19 pandemic, the reproduction number of COVID-19 swarmed in the scientific community and public media due to its simplicity in explaining an infectious disease dynamic. This paper aims to estimate the effective reproduction number (Rt) for COVID-19 over time in Bangladesh and its districts using reported cases. Methods Adapted methods derived from Bettencourt and Ribeiro (2008), which is a sequential Bayesian approach using the compartmental Susceptible-Infectious-Recovered (SIR) model, have been used to estimate Rt. Findings As of July 21, the mean Rt is 1.32(0.98-1.70, 90% HDI), with a median of 1.16(0.99-1.34 90% HDI). The initial Rt of Bangladesh was 3, whereas the Rt on the day of imposing nation-wide lockdown was 1.47, at the end of lockdown phase 1 was 1.06, at the end of lockdown phase 2 was 1.33. Each phase of nation-wide lockdown has contributed to the decline of effective reproduction number (Rt) for Bangladesh by 28.44%, and 26.70%, respectively, implying moderate effectiveness of the epidemic response strategies. Interpretation and Conclusion The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh. The Rt continued to fall below the threshold value one steadily from the beginning of July and sustained around 1. The mean Rt fell by 13.55% from May 31 to July 21, 2020, despite easing of lockdown in Bangladesh. As of July 21, the current estimate of Rt is 1.07(0.92-1.15: 90% HDI), meaning that an infected individual is spreading the virus to an average of one other, with 0.07 added chance of infecting a second individual. This whole research recommends two things- broader testing and careful calibration of measures to keep Rt a long way below the crucial threshold one.","rel_num_authors":8,"rel_authors":[{"author_name":"Al-Ekram Elahee Hridoy","author_inst":"Department of Geography and Environmental Studies, University of Chittagong"},{"author_name":"Mohammad Naim","author_inst":"Department of Electrical and Computer Engineering, North South University"},{"author_name":"Edris Alam","author_inst":"Integrated Emergency Management and Business Continue Program, Rabdan Academy"},{"author_name":"Nazim Uddin Emon","author_inst":"Department of Pharmacy, International Islamic University Chittagong"},{"author_name":"Imrul Hasan Tipo","author_inst":"Department of Biochemistry and Molecular Biology, University of Chittagong"},{"author_name":"Shekh Md. Shajid Hasan Tusher","author_inst":"Department of Geography and Environmental Studies, University of Chittagong"},{"author_name":"Safaet Alam","author_inst":"Department of Pharmaceutical Chemistry, University of Dhaka"},{"author_name":"Mohammad Safiqul Islam","author_inst":"Noakhali Science and Technology University"},{"author_name":"Longhua Guo","author_inst":"University of California, Los Angeles"},{"author_name":"James Boocock","author_inst":"University of California, Los Angeles"},{"author_name":"Scott W. Simpkins","author_inst":"Octant Inc."},{"author_name":"Isabella Lin","author_inst":"University of California, Los Angeles"},{"author_name":"Nathan LaPierre","author_inst":"University of California, Los Angeles"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.239046","rel_title":"Phylogenetic analysis of SARS-CoV-2 data is difficult","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.239046","rel_abs":"Numerous studies covering some aspects of SARS-CoV-2 data analyses are being published on a daily basis, including a regularly updated phylogeny on nextstrain.org. Here, we review the difficulties of inferring reliable phylogenies by example of a data snapshot comprising all virus sequences available on May 5, 2020 from gisaid.org. We find that it is difficult to infer a reliable phylogeny on these data due to the large number of sequences in conjunction with the low number of mutations. We further find that rooting the inferred phylogeny with some degree of confidence either via the bat and pangolin outgroups or by applying novel computational methods on the ingroup phylogeny does not appear to be possible. Finally, an automatic classification of the current sequences into sub-classes based on statistical criteria is also not possible, as the sequences are too closely related. We conclude that, although the application of phylogenetic methods to disentangle the evolution and spread of COVID-19 provides some insight, results of phylogenetic analyses, in particular those conducted under the default settings of current phylogenetic inference tools, as well as downstream analyses on the inferred phylogenies, should be considered and interpreted with extreme caution.","rel_num_authors":13,"rel_authors":[{"author_name":"Benoit Morel","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Pierre Barbera","author_inst":"Heidelberg Institute for Theoretical Studies"},{"author_name":"Lucas Czech","author_inst":"Department of Plant Biology, Carnegie Institution for Science, Stanford, CA, USA"},{"author_name":"Ben Bettisworth","author_inst":"Heidelberg Institute for Theoretical Studies"},{"author_name":"Lukas Huebner","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Sarah Lutteropp","author_inst":"Heidelberg Institute for Theoretical Studies"},{"author_name":"Dora Serdari","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Evangelia-Georgia Kostaki","author_inst":"Department of Hygiene Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"author_name":"Ioannis Mamais","author_inst":"Department of Health Sciences, European University Cyprus, Nicosia-Cyprus"},{"author_name":"Alexey Kozlov","author_inst":"Heidelberg Institute for Theoretical Studies gGmbH"},{"author_name":"Pavlos M Pavlidis","author_inst":"Foundation for Research and Technology, Hellas"},{"author_name":"Dimitrios Paraskevis","author_inst":"National and Kapoditrian University of Athens, Medical School"},{"author_name":"Alexandros Stamatakis","author_inst":"HITS gGmbH"},{"author_name":"Duke Hong","author_inst":"University of California, Los Angeles"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"evolutionary biology"},{"rel_doi":"10.1101\/2020.08.06.240325","rel_title":"Signatures and mechanisms of efficacious therapeutic ribonucleotides against SARS-CoV-2 revealed by analysis of its replicase using magnetic tweezers","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.240325","rel_abs":"Coronavirus Disease 2019 (COVID-19) results from an infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the third coronavirus outbreak to plague humanity this century. Currently, the most efficacious therapeutic against SARS-CoV-2 infection is the Remdesivir (RDV), an adenine-like ribonucleotide analogue that is very efficiently incorporated by the SARS-CoV-2 replicase. Understanding why RDV is so well incorporated will facilitate development of even more effective therapeutics. Here, we have applied a high-throughput, single-molecule, magnetic-tweezers platform to study thousands of cycles of nucleotide addition by the SARS-CoV-2 replicase in the absence and presence of RDV, a Favipiravir-related analog (T-1106), and the endogenously produced ddhCTP. Our data are consistent with two parallel catalytic pathways of the replicase: a high-fidelity catalytic (HFC) state and a low-fidelity catalytic (LFC) state, the latter allowing the slow incorporation of both cognate and non-cognate nucleotides. ddhCTP accesses HFC, T-1106 accesses LFC as a non-cognate nucleotide, while RDV efficiently accesses both LFC pathway. In contrast to previous reports, we provide unequivocal evidence against RDV functioning as a chain terminator. We show that RDV incorporation transiently stalls the replicase, only appearing as termination events when traditional, gel-based assays are used. The efficiency of ddhCTP utilization by the SARS-CoV-2 replicase suggests suppression of its synthesis during infection, inspiring new therapeutic strategies. Use of this experimental paradigm will be essential to the development of therapeutic nucleotide analogs targeting polymerases.","rel_num_authors":14,"rel_authors":[{"author_name":"Mona Seifert","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Subhas C. Bera","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Pauline van Nies","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Robert N. Kirchdoerfer","author_inst":"University of Wisconsin-Madison"},{"author_name":"Ashleigh Shannon","author_inst":"Architecture et Fonction des Macromolecules Biologiques, CNRS and Aix-Marseille Universite, UMR 7257, Polytech Case 925, 13009 Marseille, France."},{"author_name":"Thi-Tuyet-Nhung Le","author_inst":"Architecture et Fonction des Macromolecules Biologiques, CNRS and Aix-Marseille Universite, UMR 7257, Polytech Case 925, 13009 Marseille, France."},{"author_name":"Tyler L. Grove","author_inst":"Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA Institute for Protein Innovation, Boston, MA, USA"},{"author_name":"Flavia S. Papini","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Jamie J. Arnold","author_inst":"Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27514 USA"},{"author_name":"Steven C. Almo","author_inst":"Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA Institute for Protein Innovation, Boston, MA, USA"},{"author_name":"Bruno Canard","author_inst":"Architecture et Fonction des Macromolecules Biologiques, CNRS and Aix-Marseille Universite, UMR 7257, Polytech Case 925, 13009 Marseille, France."},{"author_name":"Martin Depken","author_inst":"Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands"},{"author_name":"Craig E. Cameron","author_inst":"Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27514 USA"},{"author_name":"David Dulin","author_inst":"Junior Research Group 2, Interdisciplinary Center for Clinical Research, Friedrich-Alexander-University Erlangen-Nurnberg (FAU), Cauerstr. 3, 91058 Erlangen, Ge"},{"author_name":"Yi Zhang","author_inst":"University of California, Los Angeles"},{"author_name":"Gabriel Oland","author_inst":"University of California Los Angeles"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc","type":"new results","category":"biophysics"},{"rel_doi":"10.1101\/2020.08.05.20169128","rel_title":"Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169128","rel_abs":"Abstract Objectives:To investigate longitudinal trajectory of SARS-CoV-2 neutralising antibodies and the performance of serological assays in diagnosing prior infection and predicting serum neutralisation titres with time Design Retrospective longitudinal analysis of a COVID19 case cohort . Setting NHS outpatient clinics Participants Individuals with RT-PCR diagnosed SARS-CoV-2 infection that did not require hospitalization Main outcome measures The sensitivity with which prior infection was detected and quantitative antibody titres were assessed using four SARS-CoV-2 serologic assay platforms. Two platforms employed SARS-CoV-2 spike (S) based antigens and two employed nucleocapsid (N) based antigens. Serum neutralising antibody titres were measured using a validated pseudotyped virus SARS-CoV-2 neutralisation assay. The ability of the serological assays to predict neutralisation titres at various times after PCR diagnosis was assessed. Results The three of the four serological assays had sensitivities of 95 to100% at 21-40 days post PCR-diagnosis, while a fourth assay had a lower sensitivity of 85%. The relative sensitivities of the assays changed with time and the sensitivity of one assay that had an initial sensitivity of >95% declined to 85% at 61-80 post PCR diagnosis, and to 71% at 81-100 days post diagnosis. Median antibody titres decreased in one serologic assay but were maintained over the observation period in other assays. The trajectories of median antibody titres measured in serologic assays over this time period were not dependent on whether the SARS-CoV-2 N or S proteins were used as antigen source. A broad range of SARS-CoV-2 neutralising titres were evident in individual sera, that decreased over time in the majority of participants; the median neutralisation titre in the cohort decreased by 45% over 4 weeks. Each of the serological assays gave quantitative measurements of antibody titres that correlated with SARS-CoV-2 neutralisation titres, but, the S-based serological assay measurements better predicted serum neutralisation potency. The strength of correlation between serologic assay results and neutralisation titres deteriorated with time and decreases in neutralisation titres in individual participants were not well predicted by changes in antibody titres measured using serologic assays. Conclusions: SARS-CoV-2 serologic assays differed in their comparative diagnostic performance over time. Different assays are more or less well suited for surveillance of populations for prior infection versus prediction of serum neutralisation potency. Continued monitoring of declining neutralisation titres during extended follow up should facilitate the establishment of appropriate serologic correlates of protection against SARS-CoV-2 reinfection.","rel_num_authors":16,"rel_authors":[{"author_name":"Frauke Muecksch","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Helen Wise","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Becky Batchelor","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Maria Squires","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Elizabeth Semple","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Claire Richardson","author_inst":"University Hospital Monklands, NHS Lanarkshire, Airdrie ML6 0JS"},{"author_name":"Jacqueline McGuire","author_inst":"University Hospital Monklands, NHS Lanarkshire, Airdrie ML6 0JS"},{"author_name":"Sarah Cleary","author_inst":"University Hospital Monklands, NHS Lanarkshire, Airdrie ML6 0JS"},{"author_name":"Elizabeth Furrie","author_inst":"Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY"},{"author_name":"Neil Greig","author_inst":"Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY"},{"author_name":"Gordon Hay","author_inst":"Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY"},{"author_name":"Kate Templeton","author_inst":"Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh EH16 4SA"},{"author_name":"Julio C.C. Lorenzi","author_inst":"Laboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Theodora Hatziioannou","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Sara J Jenks","author_inst":"NHS Lothian"},{"author_name":"Paul Bieniasz","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20169078","rel_title":"Transient dynamics of SARS-CoV-2 as England exited national lockdown","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169078","rel_abs":"Control of the COVID-19 pandemic requires a detailed understanding of prevalence of SARS-CoV-2 virus in the population. Case-based surveillance is necessarily biased towards symptomatic individuals and sensitive to varying patterns of reporting in space and time. The real-time assessment of community transmission antigen study (REACT-1) is designed to overcome these limitations by obtaining prevalence data based on a nose and throat swab RT-PCR test among a representative community-based sample in England, including asymptomatic individuals. Here, we describe results comparing rounds 1 and 2 carried out during May and mid June \/ early July 2020 respectively across 315 lower tier local authority areas. In round 1 we found 159 positive samples from 120,620 tested swabs while round 2 there were 123 positive samples from 159,199 tested swabs, indicating a downwards trend in prevalence from 0.13% (95% CI, 0.11%, 0.15%) to 0.077% (0.065%, 0.092%), a halving time of 38 (28, 58) days, and an R of 0.89 (0.86, 0.93). The proportion of swab-positive participants who were asymptomatic at the time of sampling increased from 69% (61%, 76%) in round 1 to 81% (73%, 87%) in round 2. Although health care and care home workers were infected far more frequently than other workers in round 1, the odds were markedly reduced in round 2. Age patterns of infection changed between rounds, with a reduction by a factor of five in prevalence in 18 to 24 year olds. Our data were suggestive of increased risk of infection in Black and Asian (mainly South Asian) ethnicities. Using regional and detailed case location data, we detected increased infection intensity in and near London. Under multiple sensitivity analyses, our results were robust to the possibility of false positives. At the end of the initial lockdown in England, we found continued decline in prevalence and a shift in the pattern of infection by age and occupation. Community-based sampling, including asymptomatic individuals, is necessary to fully understand the nature of ongoing transmission.","rel_num_authors":14,"rel_authors":[{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Kylie E. C. Ainslie","author_inst":"Imperial College London"},{"author_name":"Oliver Eales","author_inst":"Imperial College London"},{"author_name":"Caroline E Walters","author_inst":"Imperial College London"},{"author_name":"Haowei Wang","author_inst":"Imperial College London"},{"author_name":"Christina J Atchison","author_inst":"Imperial College London"},{"author_name":"Peter Diggle","author_inst":"Lancaster University"},{"author_name":"Deborah Ashby","author_inst":"Imperial College London"},{"author_name":"Christl A. Donnelly","author_inst":"Imperial College London"},{"author_name":"Graham Cooke","author_inst":"Imperial College Healthcare NHS Trust"},{"author_name":"Wendy Barclay","author_inst":"Imperial College London"},{"author_name":"Helen Ward","author_inst":"Imperial College London"},{"author_name":"Ara Darzi","author_inst":"Imperial College Healthcare NHS Trust"},{"author_name":"Paul Elliott","author_inst":"Imperial College London School of Public Health"},{"author_name":"Sara J Jenks","author_inst":"NHS Lothian"},{"author_name":"Paul Bieniasz","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168963","rel_title":"Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168963","rel_abs":"Repeat molecular testing for SARS-CoV-2 may result in scenarios including multiple positive results, positive test results after negative tests, and repeated false negative results in symptomatic individuals. Consecutively collected specimens from a retrospective cohort of COVID-19 patients at the Johns Hopkins Hospital were assessed for RNA and infectious virus shedding. Whole genome sequencing confirmed the virus genotype in patients with prolonged viral RNA shedding and droplet digital PCR (ddPCR) was used to assess the rate of false negative standard of care PCR results. Recovery of infectious virus was associated with Ct values of 18.8 {+\/-} 3.4. Prolonged viral RNA shedding was associated with recovery of infectious virus in specimens collected up to 20 days after the first positive result in patients who were symptomatic at the time of specimen collection. The use of Ct values and clinical symptoms provides a more accurate assessment of the potential for infectious virus shedding.","rel_num_authors":15,"rel_authors":[{"author_name":"Victoria Gniazdowski","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"C. Paul Morris","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Shirlee Wohl","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Thomas Mehoke","author_inst":"Johns Hopkins University Applied Physics Laboratory"},{"author_name":"Srividya Ramakrishnan","author_inst":"Johns Hopkins University"},{"author_name":"Peter Thielen","author_inst":"Johns Hopkins University Applied Physics Laboratory"},{"author_name":"Harrison Powell","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Brendan D Smith","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Derek T Armstrong","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Monica Herrera","author_inst":"Bio-Rad Laboratories"},{"author_name":"Carolyn Reifsnyder","author_inst":"Bio-Rad Laboratories"},{"author_name":"Maria Sevdali","author_inst":"Bio-Rad Laboratories"},{"author_name":"Karen C Carroll","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Andrew Pekosz","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Heba H Mostafa","author_inst":"Johns Hopkins University School of Medicine"},{"author_name":"Paul Bieniasz","author_inst":"Laboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10065"},{"author_name":"Bianca Judy Choe","author_inst":"University of California, Los Angeles"},{"author_name":"Sukantha Chandrasekaran","author_inst":"University of California, Los Angeles"},{"author_name":"Evann E. Hilt","author_inst":"University of California, Los Angeles"},{"author_name":"Manish J. Butte","author_inst":"University of California, Los Angeles"},{"author_name":"Robert Damoiseaux","author_inst":"University of California, Los Angeles"},{"author_name":"Aaron R. Cooper","author_inst":"Octant Inc."},{"author_name":"Yi Yin","author_inst":"University of California, Los Angeles"},{"author_name":"Lior Pachter","author_inst":"California Institute of Technology"},{"author_name":"Omai B. Garner","author_inst":"University of California, Los Angeles"},{"author_name":"Jonathan Flint","author_inst":"University of California, Los Angeles"},{"author_name":"Eleazar Eskin","author_inst":"University of California, Los Angeles"},{"author_name":"Chongyuan Luo","author_inst":"University of California, Los Angeles"},{"author_name":"Sriram Kosuri","author_inst":"Octant Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168435","rel_title":"First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168435","rel_abs":"Background NVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in healthy adults. Methods This is a randomized, observer-blinded, placebo-controlled, phase 1 trial in 131 healthy adults. Trial vaccination comprised two intramuscular injections, 21 days apart. Primary outcomes were reactogenicity, safety labs, and immunoglobulin G (IgG) anti-spike protein response. Secondary outcomes included adverse events, wild-type virus neutralizing antibody, and T-cell responses. Results Participants received NVX-CoV2373 with or without Matrix-M1 (n=106) or placebo (n=25). There were no serious adverse events. Reactogenicity was mainly mild in severity and of short duration (mean [&ge;] 2 days), with second vaccinations inducing greater local and systemic reactogenicity. The adjuvant significantly enhanced immune responses and was antigen dose-sparing, and the two-dose 5g NVX-CoV2373\/Matrix-M1 vaccine induced mean anti-spike IgG and neutralizing antibody responses that exceeded the mean responses in convalescent sera from COVID-19 patients with clinically significant illnesses. The vaccine also induced antigen-specific T cells with a largely T helper 1 (Th1) phenotype. Conclusions NVX-CoV2373\/Matrix-M1 was well tolerated and elicited robust immune responses (IgG and neutralization) four-fold higher than the mean observed in COVID-19 convalescent serum from participants with clinical symptoms requiring medical care and induced CD4+ T-cell responses biased toward a Th1 phenotype. These findings suggest that the vaccine may confer protection and support transition to efficacy evaluations to test this hypothesis. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).","rel_num_authors":29,"rel_authors":[{"author_name":"Cheryl Keech","author_inst":"Novavax, Inc."},{"author_name":"Gary Albert","author_inst":"Novavax, Inc."},{"author_name":"Patricia Reed","author_inst":"Novavax, Inc."},{"author_name":"Susan Neal","author_inst":"Novavax, Inc."},{"author_name":"Joyce S. Plested","author_inst":"Novavax, Inc."},{"author_name":"Mingzhu Zhu","author_inst":"Novavax, Inc."},{"author_name":"Shane Cloney-Clark","author_inst":"Novavax, Inc."},{"author_name":"Haixia Zhou","author_inst":"Novavax, Inc."},{"author_name":"Nita Patel","author_inst":"Novavax, Inc."},{"author_name":"Matthew B. Frieman","author_inst":"University of Maryland School of Medicine"},{"author_name":"Robert E. Haupt","author_inst":"University of Maryland School of Medicine"},{"author_name":"James Logue","author_inst":"University of Maryland School of Medicine"},{"author_name":"Marisa McGrath","author_inst":"University of Maryland School of Medicine"},{"author_name":"Stuart Weston","author_inst":"University of Maryland School of Medicine"},{"author_name":"Pedro A. Piedra","author_inst":"Baylor University College of Medicine"},{"author_name":"Iksung Cho","author_inst":"Novavax, Inc."},{"author_name":"Andreana Robertson","author_inst":"Novavax, Inc."},{"author_name":"Chinar Desai","author_inst":"Novavax, Inc."},{"author_name":"Kathleen Callahan","author_inst":"Novavax, Inc."},{"author_name":"Maggie Lewis","author_inst":"Novavax, Inc."},{"author_name":"Patricia Price-Abbott","author_inst":"Novavax, Inc."},{"author_name":"Neil Formica","author_inst":"Novavax, Inc."},{"author_name":"Vivek Shinde","author_inst":"Novavax, Inc."},{"author_name":"Louis Fries","author_inst":"Novavax, Inc."},{"author_name":"Jason D. Linkliter","author_inst":"Nucleus Network Pty Ltd"},{"author_name":"Paul Griffin","author_inst":"Q-Pharm"},{"author_name":"Bethanie Wilkinson","author_inst":"Novavax, Inc."},{"author_name":"Gale Smith","author_inst":"Novavax, Inc."},{"author_name":"Gregory M. Glenn","author_inst":"Novavax, Inc."},{"author_name":"Leonid Kruglyak","author_inst":"University of California, Los Angeles"},{"author_name":"Valerie A. Arboleda","author_inst":"University of California, Los Angeles"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20168872","rel_title":"Inflammasome activation in COVID-19 patients","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20168872","rel_abs":"Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1{beta} and IL-18. Although the participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease is unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and it is active in COVID-19, influencing the clinical outcome of the disease. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of post-mortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that the inflammasome is key in the pathophysiology of the disease, indicating this platform as a marker of disease severity and a potential therapeutic target for COVID-19.","rel_num_authors":45,"rel_authors":[{"author_name":"Tamara S Rodrigues","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Keyla SG Sa","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Adriene Y Ishimoto","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Amanda Becerra","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Samuel Oliveira","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Leticia Almeida","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Augusto V Goncalves","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.05.20169086","rel_title":"An Examination of School Reopening Strategies during the SARS-CoV-2 Pandemic","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169086","rel_abs":"The SARS-CoV-2 pandemic led to the closure of nearly all K-12 schools in the United States of America in March 2020. Although reopening K-12 schools for in-person schooling is desirable for many reasons, officials also understand that risk reduction strategies and detection of cases must be in place to allow children to safely return to school. Furthermore, the consequences of reclosing recently reopened schools are substantial and impact teachers, parents, and ultimately the educational experience in children. Using a stratified Susceptible-Exposed-Infected-Removed model, we explore the influences of reduced class density, transmission mitigation (such as the use of masks, desk shields, frequent surface cleaning, or outdoor instruction), and viral detection on cumulative prevalence. Our model predicts that a combination of all three approaches will substantially reduce SARS-CoV-2 prevalence. The model also shows that reduction of class density and the implementation of rapid viral testing, even with imperfect detection, have greater impact than moderate measures for transmission mitigation.","rel_num_authors":7,"rel_authors":[{"author_name":"Alfonso Landeros","author_inst":"University of California, Los Angeles"},{"author_name":"Xiang Ji","author_inst":"Tulane University"},{"author_name":"Kenneth L. Lange","author_inst":"University of California, Los Angeles"},{"author_name":"Timothy C. Stutz","author_inst":"University of California, Los Angeles"},{"author_name":"Jason Xu","author_inst":"Duke University"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.05.20169094","rel_title":"U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169094","rel_abs":"With the number of confirmed COVID-19 cases rapidly growing in the U.S., many states are experiencing a shortage of hospital-especially ICU-beds. In addition to discharging non-critical patients, expanding local hospitals' capacity as well as re-opening closed healthcare facilities, these states are actively building or converting public venues into field hospitals to fill the gap1. By studying these makeshift hospitals, we found that the states most severely impacted by the pandemic are fast at responding with the first wave of hospitals opening around the date of peak demand and the majority ready to use by the end of April. However, depending on the types of patients the field hospitals accept (COVID-19 vs. non-COVID-19) and how they are incorporated to local healthcare system, these field hospitals have utilization rate ranging from 100% to 0%. The field hospitals acting as alternative site to treat non-COVID-19 patients typically had low utilization rate and often faced the risk of COVID-19 outbreak in the facility. As overflow facilities, the field hospitals providing intensive care were highly relied on by local healthcare systems whereas the field hospitals dedicated to patients with mild symptoms often found it hard to fill the beds due to a combination of factors such as strict regulation on transferring patients from local hospitals, complication of health insurance discouraging health-seeking behavior, and effective public health measure to \"flatten the curve\" so that the additional beds were no longer needed.","rel_num_authors":4,"rel_authors":[{"author_name":"Luorongxin Yuan","author_inst":"Department of Biology, Johns Hopkins University"},{"author_name":"Sherryn Sherryn","author_inst":"International Health, Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Peter Hu","author_inst":"Department Of Anesthesiology, University of Maryland, School of Medicine"},{"author_name":"Fenghao Chen","author_inst":"The Hopkins Club for Innovation and Entrepreneurship"},{"author_name":"Jason Xu","author_inst":"Duke University"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"health systems and quality improvement"},{"rel_doi":"10.1101\/2020.08.05.20157768","rel_title":"Health systems trust in the time of Covid-19 pandemic in Bangladesh: A qualitative exploration","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20157768","rel_abs":"Background: Lack of trust hinders care seeking, and limits community support for contact tracing, care seeking, information and communication uptake, multisectoral or multi-stakeholder engagement, and community participation. We aimed at exploring how trust might be breached and what implications this may have in COVID-19 pandemic response by the Bangladesh health systems. Methods: We conducted this qualitative research during the pandemic, through seven online focus group discussions, with purposively selected mixed-gender groups of clinicians and non-clinicians (n=50). Data were analyzed through conventional content analysis method. Results: The common thread throughout the findings was the pervasive mistrust of the people in Bangladeshi health systems in its management of COVID-19 pandemic. In addition to the existing health systems weaknesses, few others became evident throughout the progression of the pandemic, namely, the lack of coordination challenges during the preparatory phase as well as the advanced stages of the pandemic. This; compounded by the health systems and political leadership failures, lead to opportunistic corruption and lack of regulations; leading to low quality, discriminatory, or no service at all. These have trust implications, manifested in health seeking from unqualified providers, non-adherence to health advice, tension between the service seekers and providers, disapproval of the governance mechanism, misuse of already scarce resources, disinterest in community participation, and eventually loss of life and economy. Conclusions: Health sector stewards should learn the lessons from other countries, ensure multisectoral engagement involving the community and political forces, and empower the public health experts to organize and consolidate a concerted health systems effort in gaining trust in the short run, and building a resilient and responsive health system in the long.","rel_num_authors":3,"rel_authors":[{"author_name":"Taufique Joarder","author_inst":"Public Health Foundation, Bangladesh"},{"author_name":"Muhammad Nahian Bin Khaled","author_inst":"International Food Policy Research Institution (IFPRI)"},{"author_name":"Shahaduz Zaman","author_inst":"Medical Anthropology and Global Health (Global Health and Infection), Brighton and Sussex Medical School, University of Sussex, UK"},{"author_name":"Fenghao Chen","author_inst":"The Hopkins Club for Innovation and Entrepreneurship"},{"author_name":"Jason Xu","author_inst":"Duke University"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"health policy"},{"rel_doi":"10.1101\/2020.08.05.20169037","rel_title":"Analysis of SIR-Network Model on COVID-19 with respect to its impact on West Bengal in India","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20169037","rel_abs":"The recent global pandemic of SARS-CoV-2 (COVID-19) disease has prompted many researchers to formulate lock-down and quarantine scenarios while the main concern of the researchers is to model the spread and the possible duration of the COVID-19 infections and also research on how long this is going to last. It seems that most of the researchers have recognized lock-down as one of the major impact factors in their models. As a result of this in the absence of lock-down the models formulated would not contribute much significant results. Hence, in this work we decide to formulate a mathematical model which would be able to predict the spread and also the possible duration of the pandemic, by considering both partial lock-down and the corresponding unlocking situations. Employing SIR-network models and taking the various districts of highly populated areas of West Bengal, India as the nodes or vertices we attempt to model the spread and duration of the pandemic during both partial lock-down and unlock phases but separately. We consider the populations where the locally present people and the people who have undergone migration of some shorts are well mixed together. In the network that we have provided the pointed edges refer to the migrating workers that is those that move away from their regular habitats in want of work. We use this research to study not only the trends that are associated with COVID-19 outbreaks, but also to study the impacts of the Government policies and the improvisation of medical facilities on this outbreak in West Bengal. At the end, we attempt to throw light upon the crisis that the economy of the state may have to go through separately on partial lock-down and unlocking scenarios.","rel_num_authors":5,"rel_authors":[{"author_name":"Debnarayan Khatua","author_inst":"Global Institute of Science and Technology"},{"author_name":"Debashree Guha","author_inst":"IIT Kharagpur, India"},{"author_name":"Samarjit Kar","author_inst":"NIT Durgapur, India"},{"author_name":"Anupam De","author_inst":"Haldia Institute of Technology, India"},{"author_name":"Eshan Samanta","author_inst":"Global Institute of Science and Technology, India"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.08.05.20167411","rel_title":"Impact of COVID-19 on the Psychological Well-Being and Turnover Intentions of Frontline Nurses in the Community: A Cross-Sectional Study in the Philippines","rel_date":"2020-08-06","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.05.20167411","rel_abs":"Purpose: This study aimed to assess fear of COVID-19 among nurses in a community setting. Methods: This study employed a cross-sectional design using self-report questionnaires. Findings: Results revealed that nurses display moderate to high fear of COVID-19 and that the female gender is correlated to fear of the virus. Moreover, the nurses fear influences their psychological distress and organizational and professional turnover intentions. Conclusion: Fear of COVID-19 is universal among nurses. There is a need to assess the factors associated with the fear to better address the nurses psychological well-being and to avoid turnover intentions.","rel_num_authors":2,"rel_authors":[{"author_name":"Janet Alexis A. De los Santos","author_inst":"Visayas State University, Philippines"},{"author_name":"Leodoro J. Labrague","author_inst":"Sultan Qaboos University, Oman"},{"author_name":"Samarjit Kar","author_inst":"NIT Durgapur, India"},{"author_name":"Anupam De","author_inst":"Haldia Institute of Technology, India"},{"author_name":"Eshan Samanta","author_inst":"Global Institute of Science and Technology, India"},{"author_name":"Mary E. Sehl","author_inst":"University of California, Los Angeles"},{"author_name":"Janet S. Sinsheimer","author_inst":"University of California, Los Angeles"},{"author_name":"Debora B Perucello","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Warrison A Andrade","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.08.05.238998","rel_title":"Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.05.238998","rel_abs":"This study characterized a genetically adapted Pseudomonas aeruginosa small colony variant isolated from a COVID-19 patient who suffered persistent bacterial coinfection and eventually recovered from critical illness. Specification and modification of the isolates discovered at genomic and transcriptomic levels with aligned phenotypic observations indicated that these isolates formed excessive biofilm with elevated quorum sensing systems.","rel_num_authors":9,"rel_authors":[{"author_name":"Zhao Cai","author_inst":"School  of Medicine, Southern University of Science and Technology"},{"author_name":"Yumei Liu","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"XiangKe Duan","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Shuhong Han","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Yuao Zhu","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Yingdan Zhang","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Chao Zhuo","author_inst":"The state key laboratory of respiratory diseases, the first affiliated hospital of Guangzhou Medical University"},{"author_name":"Yang Liu","author_inst":"Medical Research Center, Southern University of Science and Technology Hospital, 518055, Shenzhen, China"},{"author_name":"Liang Yang","author_inst":"School of Medicine, Southern University of Science and Technology"},{"author_name":"Ricardo Castro","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Flavio P Veras","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Juliana E Toller-Kawahisa","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Daniele C Nascimento","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Mikhael HF de Lima","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Camila MS Silva","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Diego B Caetite","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.08.06.239798","rel_title":"IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection","rel_date":"2020-08-06","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.08.06.239798","rel_abs":"The novel virus SARS-CoV-2 has infected more than 14 million people worldwide resulting in the Coronavirus disease 2019 (COVID-19). Limited information on the underlying immune mechanisms that drive disease or protection during COVID-19 severely hamper development of therapeutics and vaccines. Thus, the establishment of relevant animal models that mimic the pathobiology of the disease is urgent. Rhesus macaques infected with SARS-CoV-2 exhibit disease pathobiology similar to human COVID-19, thus serving as a relevant animal model. In the current study, we have characterized the transcriptional signatures induced in the lungs of juvenile and old rhesus macaques following SARS-CoV-2 infection. We show that genes associated with Interferon (IFN) signaling, neutrophil degranulation and innate immune pathways are significantly induced in macaque infected lungs, while pathways associated with collagen formation are downregulated. In COVID-19, increasing age is a significant risk factor for poor prognosis and increased mortality. We demonstrate that Type I IFN and Notch signaling pathways are significantly upregulated in lungs of juvenile infected macaques when compared with old infected macaques. These results are corroborated with increased peripheral neutrophil counts and neutrophil lymphocyte ratio in older individuals with COVID-19 disease. In contrast, pathways involving VEGF are downregulated in lungs of old infected macaques. Using samples from humans with SARS-CoV-2 infection and COVID-19, we validate a subset of our findings. Finally, neutrophil degranulation, innate immune system and IFN gamma signaling pathways are upregulated in both tuberculosis and COVID-19, two pulmonary diseases where neutrophils are associated with increased severity. Together, our transcriptomic studies have delineated disease pathways to improve our understanding of the immunopathogenesis of COVID-19 to facilitate the design of new therapeutics for COVID-19.","rel_num_authors":16,"rel_authors":[{"author_name":"Bruce A. Rosa","author_inst":"Washington University in Saint Louis School of Medicine"},{"author_name":"Mushtaq Ahmed","author_inst":"Washington University in St Louis"},{"author_name":"Dhiraj K. Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Jose Alberto Choreno-Parra","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Journey Cole","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Luis Armando Jimenez-Alvarez","author_inst":"Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias"},{"author_name":"Tatiana Sofia Rodriguez-Reyna","author_inst":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion"},{"author_name":"Bindu Singh","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Olga Golzalez","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ricardo Carrion","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Larry S. Schlesinger","author_inst":"Texas Biomedical Research Institute"},{"author_name":"John Martin","author_inst":"Washington University School of Medicine"},{"author_name":"Joaquin Zuniga","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional"},{"author_name":"Makedonka Mitreva","author_inst":"Washington University School of Medicine"},{"author_name":"Shabaana A Khader","author_inst":"Washington University School of Medicine"},{"author_name":"Deepak Kaushal","author_inst":"Texas Biomedical Research Institute"},{"author_name":"Ronaldo B Martins","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Italo A Castro","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Marjorie C Pontelli","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabio C de Barros","author_inst":"Departamento de Ecologia e Biologia Evolutiva, Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo"},{"author_name":"Natalia B do Amaral","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Marcela C Giannini","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Leticia P Bonjorno","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Isabel F Lopes","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maira N Benatti","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Rodrigo C Santana","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fernando C Vilar","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Maria Auxiliadora-Martins","author_inst":"Divisao de Medicina Intensiva, Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rodrigo Luppino-Assad","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sergio CL de Almeida","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Fabiola R de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Sabrina S Batah","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Li Siyuan","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Maira N Benatti","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Thiago M Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Jose C Alves-Filho","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fernando Q Cunha","author_inst":"Departamento de Farmacologia, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Larissa D Cunha","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Fabiani G Frantz","author_inst":"Departamento de Analises Clinicas, Toxicologicas e Bromatologia. Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Tiana Kohlsdorf","author_inst":"Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Alexandre T Fabro","author_inst":"Departamento de Patologia e Medicina Legal, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Eurico Arruda","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."},{"author_name":"Rene DR de Oliveira","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Paulo Louzada-Junior","author_inst":"Divisao de Imunologia Clinica, Emergencia, Doencas Infecciosas e Unidade de Terapia Intensiva, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paul"},{"author_name":"Dario S Zamboni","author_inst":"Departamento de Biologia Celular e Molecular e Bioagentes Patogenicos. Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo."}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"}]}



